PathoQuest offers biopharmaceutical companies a game-changing Genomic approach to secure the biosafety of biological drugs like cell & gene therapy products, vaccines, and recombinant. It allows reducing time to market of innovative treatments.

PathoQuest’s technology combines a Next-Generation Sequencing (NGS) platform with proprietary sample preparation processes completed by a proprietary pathogen genome sequence databases and automated analysis pipeline available with GLP and GMP grade.